We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Halozyme Therapeutics announced the appointment of Bernadette Connaughton to its board of directors. Connaughton brings more than 30 years of global strategic, commercial and biopharmaceutical industry expertise to the board.